Skip to main content
. 2016 Sep 20;7(42):68943–68953. doi: 10.18632/oncotarget.12126

Figure 2.

Figure 2

A. Overall survival for total patients of different post-treatment eosinophil changing groups. B. Progression free survival for patients of post-treatment eosinophil changing groups. C. Overall survival for patients with prior immunotherapy. D. Overall survival for non-ccRCC patients.